Vita Life Sciences Limited · ASX:VLS
Vita Life Sciences — H1 2019 Earnings Presentation
13 slides from Vita Life Sciences's earnings presentation, Aug 23, 2019
Slide 1: Half Year Financial Results for the 6 Months to 30 June 2019
HALF YEAR FINANCIAL RESULTS FOR THE 6 MONTHS TO 30 JUNE 2019 23 August 2019
Slide 2: Business Overview
BUSINESS OVERVIEW • Australian and Asia Pacific based pharmaceutical and healthcare over-the- counter vitamins and supplements business: formulation, packaging, distribution and sale of 3 major consumer retail brands • Over 800 registered vitamins and supplement products (SKU’s) sold in 7 countries:
Slide 3: Financial Commentary
FINANCIAL A$m GROUP SALES COMMENTARY 21 20 • Group sales of $20.4 million, up 1% on prior corresponding period • Softer retail conditions within the Australian and 19 Singaporean markets stalled revenue expectations Half Year • Net profit impacted by an additional $1.0m 2019 2018 investment in adver
Slide 4: Australia and Malaysia
AUSTRALIA MALAYSIA • Sales of $8.4million, a marginal decline of $0.1million on prior • Malaysian sales of $7.1million, an increase of 2% on PCP corresponding period (PCP) • VitaHealth brand executed a deliberate strategy to increase brand • Soft retail conditions within the traditional health food
Slide 5: Singapore and Other Asia
SINGAPORE OTHER ASIA • Sales of $3.1million, a decline of 4% over PCP • Other Asia sales of $1.7million, an increase of 29% on PCP • Market remains highly competitive amidst slowing economic • Vietnam: Continues to perform well. New channel and export environment opportunities to Vietnam are current
Slide 6: Interim Dividend & Cashflows
INTERIM DIVIDEND & Gross operating cashflow to EBITDA CASHFLOWS 120% 100% 80% • Fully franked interim dividend declared of 1.5 cents per share for HY19 (1.5 cents HY18) 60% 40% • Reduced in gross operating cashflow conversion to EBITDA mainly due to higher non-operational non- 20% cash income and ti
Slide 7: Outlook
OUTLOOK • The first half performance reflects the softer retail climate within the vitamin and supplements category across the region • Softer retail conditions expected to continue into the foreseeable future • Higher advertising and promotional costs expensed in the first half will impact full yea
Slide 8: Appendix
xs fa 2 Lu a. a. <
Slide 9: Half Year 2019 Results
HALF YEAR 2019 RESULTS Half year ended June 2019 2018 $’m $’m Revenue 20.3 20.1 EBITDA 1.8 3.0 EBIT 1.5 2.8 Profit before tax 1.5 2.8 Profit after tax 1.1 2.0 EPS (Diluted-cents) 2.06 3.76 Dividend (cents / share) 1.50 1.50
Slide 10: Balance Sheet
BALANCE SHEET Balance Sheet as at June 2019 December 2018 $m $m Current assets 24.0 24.8 Non-current assets 10.3 10.9 Total assets 34.3 35.7 Current liabilities 11.1 11.4 Non-current liabilities 2.0 1.9 Total Liabilities 13.1 13.3 Net Assets 21.2 22.4
Slide 11: Cash Flow
CASH FLOW Cash Flow for the half year ended June 2019 2018 $m $m Receipts from customers 22.9 21.5 Payments to suppliers and employees (21.9) (18.5) Gross operating cash flow 1.0 3.0 EBITDA 1.8 3.0 Gross operating cash flow / EBITDA 59.3% 100.0% Net interest (paid) (0.0) (0.1) Income tax paid (1.1)
Slide 12: Contact
CONTACT Contact: Mr Chin L Khoo, CFO: 0450 734 526 Mr Andrew O’Keefe, Managing Director: 0448 882 556 Office Telephone : +61 2 9545 2633 Website: vitalifesciences.com.au Email: enquiries@vitalifesciences.com.au Head Office: 1/ 102 Bath Road, Kirrawee, NSW 2232
Slide 13: Disclaimer
DISCLAIMER This document has been prepared by Vita Life Sciences Limited (Vita Life Sciences) and comprises written material/slides for a presentation concerning Vita Life Sciences. The presentation is for information purposes only and does not constitute or form part of any offer or invitation to a